Acumen pharmaceuticals to participate in upcoming investor conferences

Newton, mass., aug. 26, 2025 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.
ABOS Ratings Summary
ABOS Quant Ranking